111 related articles for article (PubMed ID: 37286471)
21. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
[TBL] [Abstract][Full Text] [Related]
22. Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas.
Veloso ES; Gonçalves INN; Silveira TL; Oliveira FS; Vieira DS; Cassali GD; Del Puerto HL; Ferreira E
BMC Vet Res; 2020 Jan; 16(1):24. PubMed ID: 31996230
[TBL] [Abstract][Full Text] [Related]
23. Canine cutaneous melanocytic tumours: significance of β-catenin and survivin immunohistochemical expression.
Bongiovanni L; D'Andrea A; Porcellato I; Ciccarelli A; Malatesta D; Romanucci M; Della Salda L; Mechelli L; Brachelente C
Vet Dermatol; 2015 Aug; 26(4):270-e59. PubMed ID: 25962968
[TBL] [Abstract][Full Text] [Related]
24. Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.
Oliver J; Onieva JL; Garrido-Barros M; Berciano-Guerrero MÁ; Sánchez-Muñoz A; José Lozano M; Farngren A; Álvarez M; Martínez-Gálvez B; Pérez-Ruiz E; Alba E; Cobo M; Rueda-Domínguez A; Barragán I
Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289681
[TBL] [Abstract][Full Text] [Related]
25. Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma.
Fisher NM; Schaffer JV; Berwick M; Bolognia JL
J Am Acad Dermatol; 2005 Sep; 53(3):393-406. PubMed ID: 16112344
[TBL] [Abstract][Full Text] [Related]
26. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
[TBL] [Abstract][Full Text] [Related]
27. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
28. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
29. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
[TBL] [Abstract][Full Text] [Related]
30. Expression of vitamin D receptor decreases during progression of pigmented skin lesions.
Brożyna AA; Jozwicki W; Janjetovic Z; Slominski AT
Hum Pathol; 2011 May; 42(5):618-31. PubMed ID: 21292298
[TBL] [Abstract][Full Text] [Related]
31. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
Hoffmann F; Niebel D; Aymans P; Ferring-Schmitt S; Dietrich D; Landsberg J
Clin Epigenetics; 2020 Feb; 12(1):24. PubMed ID: 32041674
[TBL] [Abstract][Full Text] [Related]
32. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
33. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Madore J; Vilain RE; Menzies AM; Kakavand H; Wilmott JS; Hyman J; Yearley JH; Kefford RF; Thompson JF; Long GV; Hersey P; Scolyer RA
Pigment Cell Melanoma Res; 2015 May; 28(3):245-53. PubMed ID: 25477049
[TBL] [Abstract][Full Text] [Related]
35. Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.
Bai X; Shoushtari AN; Betof Warner A; Si L; Tang B; Cui C; Yang X; Wei X; Quach HT; Cann CG; Zhang MZ; Pallan L; Harvey C; Kim MS; Kasumova G; Sharova T; Cohen JV; Lawrence DP; Freedman C; Fadden RM; Rubin KM; Frederick DT; Flaherty KT; Long GV; Menzies AM; Sullivan RJ; Boland GM; Johnson DB; Guo J
Br J Dermatol; 2022 Sep; 187(3):401-410. PubMed ID: 35293617
[TBL] [Abstract][Full Text] [Related]
36. Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.
Mirkina I; Hadzijusufovic E; Krepler C; Mikula M; Mechtcheriakova D; Strommer S; Stella A; Jensen-Jarolim E; Höller C; Wacheck V; Pehamberger H; Valent P
PLoS One; 2014; 9(1):e84417. PubMed ID: 24489649
[TBL] [Abstract][Full Text] [Related]
37. Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis.
McCarty MF; Bielenberg DR; Nilsson MB; Gershenwald JE; Barnhill RL; Ahearne P; Bucana CD; Fidler IJ
Melanoma Res; 2003 Aug; 13(4):379-87. PubMed ID: 12883364
[TBL] [Abstract][Full Text] [Related]
38. Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
Burgess M; Keane C; Tobin JW; Law SC; Griffin A; Gill D; Ewing AD; Atkinson V; Mollee P; Sabdia MB; Saunders NA; Gandhi MK
Acta Haematol; 2023; 146(2):166-171. PubMed ID: 36273464
[TBL] [Abstract][Full Text] [Related]
39. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.
Tas F; Keskin S; Karadeniz A; Dağoğlu N; Sen F; Kilic L; Yildiz I
Oncology; 2011; 81(5-6):353-8. PubMed ID: 22248874
[TBL] [Abstract][Full Text] [Related]
40. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
